Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,437 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,348)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06334835 | Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells. | unknown | — | 20 | IRCCS SYNLAB SDNOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06335277 | Total Body Irradiation Treatments for Patients Treated at European Institute of Oncology | unknown | — | 50 | European Institute of OncologyOTHER | 1 | Mar 28, 2024 |
| NCT03412409 | RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT | unknown | Phase 2 | 50 | Peking University People's HospitalOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT05729178 | Unravelling the Role of KCTD Protein Family in the Clinical Management of Childhood Acute Lymphoblastic Leukemias | unknown | — | 80 | IRCCS SYNLAB SDNOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT04470947 | Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies(EXALT-2) | unknown | — | 150 | Medical University of ViennaOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT06279494 | Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors | unknown | Phase 1 / Phase 2 | 6 | Peking University People's HospitalOTHER | 0 | Mar 21, 2024 | clinicaltrials |
| NCT03291444 | CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS | unknown | Phase 1 | 30 | Zhujiang HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT03407859 | Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL | unknown | Early Phase 1 | 100 | Zhujiang HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT04173988 | Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | unknown | Early Phase 1 | 6 | Children's Hospital of Fudan UniversityOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06293586 | Comparison Between Peribulbar And Sub-tenon Blocks on Oculocardiac Reflex (OCR) During Pediatric Strabismus Surgery | unknown | N/A | 140 | Cairo UniversityOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT06285136 | Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult | unknown | Phase 2 / Phase 3 | 40 | The Second Affiliated Hospital of Kunming Medical UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT06277011 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research | unknown | Early Phase 1 | 18 | Anhui Provincial HospitalOTHER_GOV | 1 | Feb 26, 2024 | clinicaltrials |
| NCT02192619 | National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup | unknown | — | 500 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05865678 | Musculoskeletal Health in Adult Haematological Cancer Survivors(SKETCh) | unknown | — | 650 | The Christie NHS Foundation TrustOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT04582487 | Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL | unknown | N/A | 32 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT04731974 | Acute Concussion and Melatonin | unknown | Phase 2 | 254 | Children's National Research InstituteOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT04358393 | A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS | unknown | Phase 1 / Phase 2 | 69 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT06233890 | The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia(TIRE) | unknown | — | 50 | Imperial College Healthcare NHS TrustOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06218771 | A Study of TQB3454 Tablets in Patients With Blood Tumors | unknown | Phase 1 / Phase 2 | 80 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06209671 | INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia | unknown | Phase 1 | 12 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 0 | Jan 17, 2024 | clinicaltrials |
| NCT04284228 | Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT | unknown | Phase 1 / Phase 2 | 22 | NexImmune Inc.INDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06188182 | D-index as a Predictor of Complication of Treatment of Patients With Acute Myeloid Leukemia | unknown | — | 60 | Assiut UniversityOTHER | 0 | Jan 3, 2024 | clinicaltrials |
| NCT04090268 | Precision Exercise in Children With Malignant Hemopathies(SportTherapy) | unknown | N/A | 380 | University of Milano BicoccaOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT06177561 | Safety and Efficacy of LPE in Clearing DSA in Patients Who Received Allo-HSCT | unknown | N/A | 38 | Ruijin HospitalOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05846672 | Turkish Cultural Adaptation, Validity and Reliability of the "Gait Outcomes Assessment List" | unknown | — | 200 | Istanbul University - CerrahpasaOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT05692713 | Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201) | unknown | — | 320 | University of British ColumbiaOTHER | 2 | Dec 8, 2023 | clinicaltrials |
| NCT06162325 | Venetoclax in Combination With Standard Induction and Consolidation Chemotherapy in Newly Diagnosed Young AML Patients | unknown | — | 45 | Peking Union Medical College HospitalOTHER | 1 | Dec 8, 2023 | clinicaltrials |
| NCT06160115 | The Role of NK Cells to Detect Blood Infection in ALL. | unknown | — | 56 | Assiut UniversityOTHER | 0 | Dec 7, 2023 | clinicaltrials |
| NCT04372524 | Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study | unknown | — | 350 | University of British ColumbiaOTHER | 2 | Dec 5, 2023 | clinicaltrials |
| NCT04663100 | Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence | unknown | N/A | 30 | University of TennesseeOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT03064269 | CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia | unknown | Phase 1 | 10 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03193281 | KISS Study: Kinase Inhibition With Sprycel Start up(KISS) | unknown | Phase 2 | 91 | University of Auckland, New ZealandOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03614858 | CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. | unknown | Phase 1 / Phase 2 | 20 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03896854 | CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 15 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT04257175 | CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression | unknown | Phase 2 / Phase 3 | 10 | Sheba Medical CenterOTHER_GOV | 1 | Nov 28, 2023 | clinicaltrials |
| NCT04989335 | Bisantrene Combination for Resistant AML | unknown | Phase 2 | 29 | Sheba Medical CenterOTHER_GOV | 1 | Nov 28, 2023 | clinicaltrials |
| NCT05025150 | Point-of-Care Ultrasound for Pediatric Thoracic Trauma: A Multi-Institutional Trial | unknown | — | 1,020 | Sutter HealthOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT05583175 | Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies | unknown | Phase 2 | 50 | Xianmin Song, MDOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT05803395 | Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy. | unknown | — | 954 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT05747157 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research | unknown | Early Phase 1 | 18 | Anhui Provincial HospitalOTHER_GOV | 1 | Nov 21, 2023 | clinicaltrials |
| NCT05918198 | Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia | unknown | Phase 2 | 52 | Peking University People's HospitalOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06141304 | Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT | unknown | Phase 2 | 28 | The First Hospital of Jilin UniversityOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06121765 | Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI | unknown | — | 45 | Assiut UniversityOTHER | 0 | Nov 8, 2023 | clinicaltrials |
| NCT04739826 | Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia | unknown | — | 491 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT06087419 | A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients | unknown | Phase 1 / Phase 2 | 42 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Nov 2, 2023 | clinicaltrials |
| NCT06111625 | Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL | unknown | Phase 2 | 20 | Sichuan UniversityOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT06110182 | Evaluation of the Advantage in the Use of Enteral Nutrition in Children Treated for Acute Lymphoblastic Leukemia | unknown | — | 300 | Central Hospital, Nancy, FranceOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT04767152 | Evaluation of Brain Changes in ALL Patients on Therapy | unknown | N/A | 110 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Oct 30, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Apr 3, 2024source: clinicaltrials